Yeh, but they have tax R&D carry forward losses that are worth another couple of dollars a share to a big profitable company. They are setting up to sell off or be bought out . A big pharma may still think the RCC market is good enough to do another trial. I'd also like to know if Astellas basically violated the Tivozanib contract, and AVEO now owns all rights. That would make it a much more attractive buy out.